|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2016-05-27 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2007-04-18 |
|
|
|
|
|
|
最高研发阶段申请上市 |
首次获批国家/地区- |
首次获批日期- |
International, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis.
Pharmacokinetic and pharmacodynamic parameters of RPH-104 multiple doses in this patient population will be assessed as well.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
The primary goal of the study is to assess the efficacy and safety of RPH-104 in subjects with Schnitzler Syndrome using Schnitzler Disease Activity Score (SDAS), which includes the Physician's Global Assessment (PGA) and the local laboratory C-reactive protein (CRP) result
International, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial infarction (STEMI)
100 项与 R-Pharm Overseas, Inc. 相关的临床结果
0 项与 R-Pharm Overseas, Inc. 相关的专利(医药)
100 项与 R-Pharm Overseas, Inc. 相关的药物交易
100 项与 R-Pharm Overseas, Inc. 相关的转化医学